LAG3 and non-small cell lung carcinoma: Recently, the phase 2b TACTI–003 trial reported that eftilagimod alpha (a soluble LAG–3 protein) plus pembrolizumab achieved favor efficacy (ORR, 38%; PFS, 6.9 months) as 1st–line treatment for advanced NSCLC (71).